J. Masliah-Planchon

This study shows that EZH2 mutations in follicular lymphoma alter H3K27 methylation and transcriptional responses to PRC2 inhibition, with clinical implications for patient stratification.

The paper develops patient-derived xenografts (PDXs) for bladder and ureteral cancers, identifies molecular subtypes, and shows that combined FGFR/EGFR inhibition is more effective than single-agent therapy for FGFR3-mutant tumors.